Davis Polk advised J.P. Morgan and BofA Merrill Lynch as representatives of the several underwriters on a $97.8 million SEC-registered offering of common stock of Esperion Therapeutics, Inc., which includes the full exercise of the underwriters’ option to purchase additional shares. The common stock is listed on the NASDAQ Global Market under the symbol “ESPR.”
Davis Polk advised Goldman, Sachs & Co. and Citigroup as joint book-running managers in connection with the $55 million initial public offering of common stock by Atara Biotherapeutics, Inc. Atara Biotherapeutics’ common stock is listed on the NASDAQ Global Select Market under the symbol “ATRA.”
Based in Brisbane, California, Atara Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle-wasting conditions and oncology.
Bingham, led by partners Floyd Wittlin and Christina Melendi, represented OM Asset Management in its recent initial public offering. The IPO offered 22 million ordinary shares of OM Asset Management at a price of $14 per share. Shares of OM Asset Management began trading on Oct. 9 on the New York Stock Exchange under the ticker symbol “OMAM.” OM Asset Management is a global, multi-boutique asset management company with approximately $221 billion of assets under management as of Aug.
Entra ASA has listed on Oslo Bors. The Entra IPO is historically one of the largest international IPOs in Norway, sizable in an European context and the first privatisation in Norway since the 2005 IPO of Cermaq.
Wikborg Rein acted as legal counsel to the Norwegian government represented by the Norwegian Ministry of Trade, Industry and Fisheries in the dual track process (IPO or trade-sale).
The core Wikborg Rein team comprised Dag Erik Rasmussen, Per Anders Saehle, Goran Mjelde Aarvik, Marianne Sahl Sveen and Ole Henrik Wille.
Simpson Thacher recently represented the underwriters led by Deutsche Bank Securities Inc., Barclays Capital Inc. and Credit Suisse Securities (USA) LLC (the “underwriters”) in connection with the offering by Trina Solar Limited (“Trina Solar”) of US$115.0 million principal amount of 4.0% Convertible Senior Notes due 2019 (the “Notes”) pursuant to Rule 144A and Regulation S, which included the exercise in full of the option to purchase an additional US$15.0 million principal amount of the Notes granted by Trina Solar.
Herbert Smith Freehills has advised Hua Hong Semiconductor Limited (Hua Hong) on its US$360 million initial public offering (IPO) on the Hong Kong Stock Exchange.
The listing and offering of shares, which were priced on 9 October 2014 and traded six days later, included Rule 144A and Regulation S tranches. Proceeds from the IPO will be used to fund capacity expansion.
Davis Polk advised Anacor Pharmaceuticals, Inc. in connection with its offering of $82.5 million aggregate principal amount of its 2% convertible senior notes due 2021 to qualified institutional buyers pursuant to Rule 144A, which included $7.5 million aggregate principal amount of convertible senior notes issued pursuant to the exercise in full of the initial purchasers’ over-allotment option.
Ashurst advised Oriel Securities as the bookrunners and sponsors on a follow on fundraising for Foresight Solar Fund ("Foresight" or the "Company"), the UK-based closed-ended investment company which listed on the LSE last year. The company raised £60.1 million in gross proceeds via an initial placing and offer for subscription on the London Stock Exchange's Main Market and has also created a placing programme of further shares over the next year.
BDT Capital Partners (“BDT”) has announced in a filing with the United States Securities and Exchange Commission that BDT had raised approximately $5.2 billion of capital commitments from over 100 investors for BDT Capital Partners Fund II, L.P. and its related parallel partnership vehicles. Cravath represented BDT in connection with the fundraising for Fund II.
The Firm represented Goldman Sachs in the initial public offering and Rule 144A/Regulation S offering by Hua Hong Semiconductor Limited. Hua Hong sold an aggregate of 228,696,000 ordinary shares in the offering (before greenshoe) and raised gross proceeds of approximately HK$2,572.8 million (US$332.0 million). The ordinary shares of Hua Hong are listed on the Hong Kong Stock Exchange. Goldman Sachs acted as sole sponsor, sole global coordinator and sole bookrunner.